story of the week
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
J. Clin. Oncol 2022 Aug 30;[EPub Ahead of Print], CJ Hoimes, TW Flaig, MI Milowsky, TW Friedlander, MA Bilen, S Gupta, S Srinivas, JR Merchan, RR McKay, DP Petrylak, C Sasse, BH Moreno, Y Yu, AS Carret, JE RosenbergFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.